Julia McEvoy

Jones Day (Washington DC)
Lawyer (Partner)

Julia E. McEvoy returned to Jones Day’s antitrust group in late 2015 after spending three years as a deputy to the third-highest ranking official at the U.S. Department of Justice, where she was tasked with overseeing the Antitrust Division and the watchdog’s other civil enforcement units. She was Deputy Associate Attorney General. Prior to joining the Government she was Partner with Jones Day. She represented corporate and individual clients in a broad range of civil and criminal litigation matters involving antitrust, corporate control, and fiduciary liability issues. She has substantial experience in all phases of complex civil and criminal cases, from prelitigation counseling and investigation through discovery, trial, and appeal. When she was in Jones Day, Julie also had extensive experience conducting internal investigations, coordinating individual and company responses to government inquiries, negotiating appropriate resolutions with government authorities, and defending individuals and companies in the civil litigation that frequently follows. For example, she acted as national coordinating counsel for 20 defendants in more than 100 state court cases brought against vitamin manufacturers following international investigations of cartel activity in the industry. Julie argued complex jurisdictional, procedural, and remedial matters on behalf of those defendants in trial and appellate courts around the country. Julie maintained an active pro bono practice and has successfully assisted political and social activists seeking asylum from abusive regimes in African and South Asian countries.

Linked authors

Jones Day (Washington DC)
Jones Day (Houston)
Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (Washington DC)

Articles

583 Bulletin

Jonathan Berman, Rosanna McCalips, Julia McEvoy, Larissa Bergin The U.S. Congress implements a new law requiring drug manufacturers to disclose biologic patent settlement agreements to antitrust Authorities (Patient Right to Know Drug Prices Act)

25

New Law Requires Disclosure of Biologic Patent Settlement Agreements to Antitrust Authorities* Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar (...)

J. Bruce McDonald, Julia McEvoy, Joseph Antel The US District Eastern Court of Virginia orders a defendant in private antitrust litigation to divest a manufacturing plant following a competitor’s merger challenge (Steves and Sons / Jeld-Wen)

34

A federal district court has ordered a defendant in private antitrust litigation to divest a manufacturing plant following a competitor’s merger challenge. Although the decision is certain to be appealed, it may embolden customers or competitors wishing to challenge a transaction and create new (...)

Send a message